Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir
Mauro Viganò(Ospedale San Giuseppe), Pietro Lampertico(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Vincenzo Occhipinti(University of Milan), F. Bronte(University of Palermo), Vincenzo Messina(Ospedale Sant'Anna), G. Grossi(University of Milan), Maurizio Russello(Ospedale Garibaldi), S. Zaltron(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Francesco Castelli(University of Brescia), Gloria Taliani(Sapienza University of Rome), Erica Villa(University of Modena and Reggio Emilia), Alfredo Marzano(University of Turin), M. Fasano(University of Bari Aldo Moro), Pietro Andreoné, Alessandra Tucci(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Aldo Marrone(University of Campania "Luigi Vanvitelli"), Sara Labanca(University of Milan), F. Facchetti(University of Milan), Teresa Santantonio(Ospedali Riuniti di Foggia), S. Fagiuoli(Ospedale Papa Giovanni XXIII), Maria Grazia Rumi(University of Milan), Giuseppina Brancaccio, R. Ganga(Azienda Ospedaliera G. Brotzu), Alessandro Loglio(Ospedale Papa Giovanni XXIII)
Cited by 10
Related Papers
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.
|Journal of Clinical Investigation|1996|661